Detrimental effects of chemotherapeutics and other drugs on the endothelium: A call for endothelial toxicity profiling

Pharmacological Reports

Volumn 67, Issue 4, 2015, Pages 811-817

  Wojcik, Tomasz ^a   Szczesny, Ewa ^a   Chlopicki, Stefan ^a,b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antidepressants; Antipsychotic agents; Chemotherapeutics; Endotheliotoxicity; Endothelium

Indexed keywords

AMITRIPTYLINE; ANTHRACYCLINE; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; BARDOXOLONE; BEVACIZUMAB; BLEOMYCIN; CHLORPROMAZINE; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FLUOXETINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PACLITAXEL; RISPERIDONE; ROFECOXIB; SERTRALINE; SORAFENIB; SUNITINIB; TORCETRAPIB; TRANYLCYPROMINE; TRASTUZUMAB; UNINDEXED DRUG; VENLAFAXINE; VINCA ALKALOID; CYCLOOXYGENASE 2 INHIBITOR;

CARDIOTOXICITY; CARDIOVASCULAR RISK; CYTOTOXICITY; ENDOTHELIAL DYSFUNCTION; HUMAN; MENTAL DISEASE; NONHUMAN; REVIEW; STRESS; VASCULAR ENDOTHELIUM; ANIMAL; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; METABOLISM; PATHOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS; ANTIPSYCHOTIC AGENTS; CYCLOOXYGENASE 2 INHIBITORS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENDOTHELIUM, VASCULAR; HUMANS;

EID: 84940461207     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2015.03.022     Document Type: Review

References (74)

1. J.P.J. Halcox, W.H. Schenke, G. Zalos, R. Mincemoyer, A. Prasad, M.A. Waclawiw, and et al. Prognostic value of coronary vascular endothelial dysfunction Circulation 106 2002 653 658
2. S. Chłopicki, and R.J. Gryglewski Angiotensin converting enzyme (ACE) reductase inhibitors in the forefront of pharmacology of endothelium Pharmacol Rep 56 2005 86 96
3. G.A. Fitzgerald Coxibs and cardiovascular disease N Engl J Med 351 2004 1709 1711
4. A.H. Mohammadpour, and F. Akhlaghi Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective Clin Pharmacokinet 52 2013 615 626
5. A. Soultati, G. Mountzios, C. Avgerinou, G. Papaxoinis, D. Pectasides, M.-A. Dimopoulos, and et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications Cancer Treat Rev 38 2012 473 483
6. C. Shenoy, I. Klem, A.L. Crowley, M.R. Patel, M.A. Winchester, C. Owusu, and et al. Cardiovascular complications of breast cancer therapy in older adults Oncologist 16 2011 1138 1143
7. C. Tan, H. Tasaka, K.-P. Yu, M.L. Murphy, and D.A. Karnofsky Daunomycin an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia Cancer 20 1967 333 353
8. C.L. Shapiro, P.H. Hardenbergh, R. Gelman, D. Blanks, P. Hauptman, A. Recht, and et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients J Clin Oncol 16 1998 3493 3501
9. S.M. Swain, F.S. Whaley, and M.S. Ewer Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials Cancer 97 2003 2869 2879
10. P.G. Steinherz, A. Redner, L. Steinherz, P. Meyers, C. Tan, and G. Heller Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol Cancer 72 1993 3120 3130
11. H. Hurwitz, and L. Fehrenbacher Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
12. M.S. Ewer, H.R. Gibbs, J. Swafford, and R.S. Benjamin Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 26 1999 96 101
13. A. Sandoo, G. Kitas, and A. Carmichael Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer Anticancer Res 1152 2014 1147 1151
14. B.C. Kuenen Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients Arterioscler Thromb Vasc Biol 22 2002 1500 1505
15. X. Zhu, K. Stergiopoulos, and S. Wu Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis Acta Oncol 48 2009 9 17
16. M.L. Telli, S.A. Hunt, R.W. Carlson, and A.E. Guardino Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility J Clin Oncol 25 2007 3525 3533
17. M. Morganti, A. Carpi, A. Nicolini, I. Gorini, B. Glaviano, M. Fini, and et al. Atherosclerosis and cancer: common pathways on the vascular endothelium Biomed Pharmacother 56 2002 317 324
18. S. Najjar, D.M. Pearlman, K. Alper, A. Najjar, and O. Devinsky Neuroinflammation and psychiatric illness J Neuroinflammation 10 2013 43
19. M.B. Wolf, and J.W. Baynes The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction Biochim Biophys Acta 1760 2006 267 271
20. B. Kalyanaraman Teaching the basics of redox biology to medical and graduate students: oxidants, antioxidants and disease mechanisms Redox Biol 1 2013 244 257
21. G. Weiss, M. Loyevsky, and V.R. Gordeuk Dexrazoxane (ICRF-187) Gen Pharmacol Vasc Syst 32 1999 155 158
22. J. Damrot, T. Nübel, B. Epe, W.P. Roos, B. Kaina, and G. Fritz Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide Br J Pharmacol 149 2006 988 997
23. A. Vavrova, H. Jansova, E. Mackova, M. Machacek, P. Haskova, L. Tichotova, and et al. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells PLOS ONE 8 2013 e76676
24. K. Tewey, T. Rowe, L. Yang, B. Halligan, and L. Liu Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II Science 226 1984 466 468
25. J.C. Wang Cellular roles of DNA topoisomerases: a molecular perspective Nat Rev Mol Cell Biol 3 2002 430 440
26. G. Capranico, S. Tinelli, C.A. Austin, M.L. Fisher, and F. Zunino Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development Biochim Biophys Acta - Gene Struct Expr 1132 1992 43 48
27. S. Zhang, X. Liu, T. Bawa-Khalfe, L.-S. Lu, Y.L. Lyu, L.F. Liu, and et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity Nat Med 18 2012 1639 1642
28. T. Wojcik, E. Buczek, K. Majzner, A. Kolodziejczyk, J. Miszczyk, W. Kwiatek, and et al. Comparative endothelial profiling of doxorubicin and daunorubicin in cultured endothelial cells Toxicol In Vitro 29 3 2015 512 521
29. K. Majzner, T. Wójcik, E. Szafraniec, M. Łukawska, I. Oszczapowicz, S. Chłopicki, and et al. Raman microspectroscopic investigation on nuclear accumulation of doxorubicin, daunorubicin and their epimers in endothelium; relationship with cytotoxicity Analyst 140 2015 2302 2310
30. E.C. Friedberg Out of the shadows and into the light: the emergence of DNA repair Trends Biochem Sci 20 1995 381
31. D. Cortez, S. Guntuku, J. Qin, and S.J. Elledge ATR and ATRIP: partners in checkpoint signaling Science 294 2001 1713 1716
32. R. Feng, W.L. Zhai, H.Y. Yang, H. Jin, and Q.X. Zhang Induction of ER stress protects gastric cancer cells against apoptosis induced by cisplatin and doxorubicin through activation of p38 MAPK Biochem Biophys Res Commun 406 2011 299 304
33. A.R. Diers, K.A. Broniowska, and N. Hogg Nitrosative stress and redox-cycling agents synergize to cause mitochondrial dysfunction and cell death in endothelial cells Redox Biol 1 2013 1 7
34. I.F. Faneyte, P.M.P. Kristel, and M.J. Van De Vijver Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer Anticancer Res 24 2004 2931 2940
35. O.S. Bains, A. Szeitz, J.M. Lubieniecka, G.E. Cragg, T.A. Grigliatti, K.W. Riggs, and et al. A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin J Pharmacol Exp Ther 347 2013 375 387
36. S. Toldo, R.W. Goehe, M. Lotrionte, E. Mezzaroma, E.T. Sumner, G.G.L. Biondi-Zoccai, and et al. Comparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouse PLOS ONE 8 2013 4 11
37. V. Kaushal, G.P. Kaushal, and P. Mehta Differential toxicity of anthracyclines on cultured endothelial cells Endothelium 11 2004 253 258
38. J. Nuver, A.J. Smit, D.T. Sleijfer, A.I. Van Gessel, A.M. Van Roon, J. Van Der Meer, and et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer Eur J Cancer 40 2004 701 706
39. D. Lechner, M. Kollars, A. Gleiss, P.A. Kyrle, and A. Weltermann Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity J Thromb Haemost 5 2007 2445 2452
40. H. Ito, T. Okafuji, and T. Suzuki Vitamin E prevents endothelial injury associated with cisplatin injection into the superior mesenteric artery of rats Heart Vessels 10 1995 178 184
41. D.J. Vaughn, S.C. Palmer, J.R. Carver, L.A. Jacobs, and E.R. Mohler Cardiovascular risk in long-term survivors of testicular cancer Cancer 112 2008 1949 1953
42. Y. Basaki, L. Chikahisa, K. Aoyagi, K. Miyadera, K. Yonekura, A. Hashimoto, and et al. Gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor Angiogenesis 4 2001 163 173
43. K.A. Hotchkiss, A.W. Ashton, R. Mahmood, R.G. Russell, J.A. Sparano, and E.L. Schwartz Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center Mol Cancer Ther 1 2002 1191 1200
44. S.C. Wood, X. Tang, and B. Tesfamariam Paclitaxel potentiates inflammatory cytokine-induced prothrombotic molecules in endothelial cells J Cardiovasc Pharmacol 55 2010 276 285
45. D.L. Kachel, and W.J. Martin Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury J Pharmacol Exp Ther 268 1994 42 46
46. B.L. Samuels, N.J. Vogelzang, and B.J. Kennedy Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy Cancer Chemother Pharmacol 19 1987 253 256
47. J.C. Barefoot, M.J. Helms, D.B. Mark, J.A. Blumenthal, R.M. Califf, T.L. Haney, and et al. Depression and long-term mortality risk in patients with coronary artery disease Am J Cardiol 78 1996 613 617
48. A. Sherwood, A.L. Hinderliter, L.L. Watkins, R.A. Waugh, and J.A. Blumenthal Impaired endothelial function in coronary heart disease patients with depressive symptomatology J Am Coll Cardiol 46 2005 656 659
49. E.V. Bouzinova, R. Norregaard, D.M.B. Boedtkjer, I.A. Razgovorova, A.M.J. Moeller, O. Kudryavtseva, and et al. Association between endothelial dysfunction and depression-like symptoms in chronic mild stress model of depression Psychosom Med 76 2014 268 276
50. R.C. Baldwin Is vascular depression a distinct sub-type of depressive disorder? A review of causal evidence Int J Geriatr Psychiatry 20 2005 1 11
51. E. Szczesny, A. Basta-Kaim, J. Slusarczyk, E. Trojan, K. Glombik, M. Regulska, and et al. The impact of prenatal stress on insulin-like growth factor-1 and pro-inflammatory cytokine expression in the brains of adult male rats: the possible role of suppressors of cytokine signaling proteins J Neuroimmunol 276 2014 37 46
52. P. Stenvinkel Endothelial dysfunction and inflammation - is there a link? Nephrol Dial Transpl 16 2001 1968 1971
53. J.W. Newcomer Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review CNS Drugs 19 Suppl. 1 2005 1 93
54. P. Mackin Cardiac side effects of psychiatric drugs Hum Psychopharmacol 23 Suppl. 1 2008 3 14
55. P.A. Ringen, J.A. Engh, A.B. Birkenaes, I. Dieset, and O.A. Andreassen Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions Front Psychiatry 5 2014 137
56. V.L. Ellingrod, S.F. Taylor, R.D. Brook, S.J. Evans, S.K. Zöllner, T.B. Grove, and et al. Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs) Schizophr Res 130 2011 20 26
57. A.-K. Israel, A. Seeck, M.K. Boettger, T. Rachow, S. Berger, A. Voss, and et al. Peripheral endothelial dysfunction in patients suffering from acute schizophrenia: a potential marker for cardiovascular morbidity? Schizophr Res 128 2011 44 50
58. D.P.J. Osborn, G. Levy, I. Nazareth, I. Petersen, A. Islam, and M.B. King Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database Arch Gen Psychiatry 64 2007 242 249
59. M. Kassan, G.F. Lasker, S.C. Sikka, S.H. Mandava, A. Gokce, K. Matrougui, and et al. Chronic escitalopram treatment induces erectile dysfunction by decreasing nitric oxide bioavailability mediated by increased nicotinamide adenine dinucleotide phosphate oxidase activity and reactive oxygen species production Urology 82 1188 2013 e1 e7
60. S. Ribback, D. Pavlovic, D. Herbst, R. Nedeljkov-Jancic, M. Wendt, V. Nedeljkov, and et al. Effects of amitriptyline, fluoxetine, tranylcypromine and venlafaxine on rat vascular smooth muscle in vitro - the role of the endothelium J Physiol Pharmacol 63 2012 119 125
61. J.M. Vila, P. Medina, G. Segarra, P. Lluch, F. Pallardó, B. Flor, and et al. Relaxant effects of antidepressants on human isolated mesenteric arteries Br J Clin Pharmacol 48 1999 223 229
62. V.L. Serebruany, A.H. Glassman, A.I. Malinin, C.B. Nemeroff, D.L. Musselman, L.T. van Zyl, and et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy Circulation 108 2003 939 944
63. S.P. Roose, F. Laghrissi-Thode, J.S. Kennedy, J.C. Nelson, J.T. Bigger, B.G. Pollock, and et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease J Am Med Assoc 279 1998 287 291
64. P. Pacher, and V. Kecskemeti Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des 10 2004 2463 2475
65. C. Spindelegger, K. Papageorgiou, R. Grohmann, R.R. Engel, W. Greil, A. Konstantinidis, and et al. Cardiovascular adverse reactions during antidepressant treatment: a drug surveillance report of German-speaking countries between 1993 and 2010 Int J Neuropsychopharmacol 18 2014
66. H. Rang, M. Dale, J. Ritter, R. Flower, and G. Henderson Rang and Dale's pharmacology Seventh ed. 2012 Elsevier Urban and Partner Wroclaw
67. C. Can Contradictory effects of chlorpromazine on endothelial cells in a rat model of endotoxic shock in association with its actions on serum TNF-α levels and antioxidant enzyme activities Pharmacol Res 48 2003 223 230
68. S. Aboul-Fotouh, and N. Elgayar Atypical antipsychotics such as risperidone, but not paliperidone, worsen vascular endothelial function via upregulation of adhesion molecules VCAM-1, ICAM-1, and E-selectin in diabetic rats Can J Physiol Pharmacol 91 2013 1119 1126
69. B. Martinc, I. Grabnar, and T. Vovk The role of reactive species in epileptogenesis and influence of antiepileptic drug therapy on oxidative stress Curr Neuropharmacol 10 2012 328 343
70. T.-Y. Tan, C.-H. Lu, H.-Y. Chuang, T.-K. Lin, C.-W. Liou, W.-N. Chang, and et al. Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis Epilepsia 50 2009 1579 1586
71. S. Van Laecke, W. Van Biesen, and R. Vanholder The paradox of bardoxolone methyl: a call for every witness on the stand? Diabetes Obes Metab 17 2015 9 14
72. S. Nadanaciva, M.D. Aleo, C.J. Strock, D.B. Stedman, H. Wang, and Y. Will Toxicity assessments of nonsteroidal anti-inflammatory drugs in isolated mitochondria, rat hepatocytes, and zebrafish show good concordance across chemical classes Toxicol Appl Pharmacol 272 2013 272 280
73. A. Bullen Microscopic imaging techniques for drug discovery Nat Rev Drug Discov 7 2008 54 67
74. H. Laverty, C. Benson, E. Cartwright, M. Cross, C. Garland, T. Hammond, and et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol 163 2011 675 693